Loading...
Loading...
Analysts at Piper Jaffray upgraded Achillion Pharmaceuticals
ACHN from Neutral to Overweight.
The target price for Achillion Pharmaceuticals has been raised from $5.00 to $10.00.
Achillion Pharmaceuticals shares have surged 14.29% over the past 52 weeks, while the S&P 500 index has gained 14.20% in the same period.
Achillion Pharmaceuticals' shares surged 7.74% to $7.93 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in